Dear Editor:
Oral iron replacement is considered standard frontline therapy for iron-deficiency anemia. 1 The effectiveness of oral iron is compromised by lack of absorption, gastrointestinal perturbation, and non-adherence to treatment estimated to range from 10% at day 14 of therapy to 32% after 2 months. [2] [3] [4] The timing for an optimal switch from oral to intravenous (IV) iron replacement therapy is not well characterized in patient care or treatment algorithms. Currently, there are no markers routinely used in clinical practice to predict response to oral iron. The oral iron challenge test is rarely used since it has not been extensively validated. 1 The primary goal of our study was to identify a practical and sensitive predictor of non-response to oral iron replacement therapy to inform decisions around transitioning to intravenous therapy in patients unlikely to benefit from oral iron. We conducted a secondary analysis of data from five randomized clinical trials (RCT) of oral iron versus (vs) IV ferric carboxymaltose to characterize response to oral iron therapy.
Complete data from the oral arms of five RCTs of iron-deficiency anemia in heavy uterine bleeding (N=1), inflammatory bowel diseases (N=1), post-partum anemia (N=2), and other etiologies (N=1) were combined for assessment of response to oral iron. [4] [5] [6] [7] [8] Inclusion criteria for the trials were similar, most included a hemoglobin (Hb) of ≤ 10 -11 g/dL and a ferritin <100 ng/ml. Responders were defined as subjects with a Hb increase of >1.0 g/dL at day 14 and nonresponders were subjects with a Hb increase of <1.0 g/dL at day 14. The analysis population was the modified intention-to-treat population of subjects randomized to oral iron in each trial who received >1 dose of assigned study medication, and had >1 post-baseline Hb test. Baseline and outcome data at day 14, day 28, and the interval from days 42 to 56 were evaluated using Hb >1.0 g/dL was more robust for subjects with post-partum anemia (95.5%) than subjects with heavy uterine bleeding (56.3%), gastrointestinal (53.5%) and other etiologies (42.9%).
The major finding from this pooled analysis of RCT data in iron-deficiency anemia was that day 14 Hb treatment response to oral iron was an accurate predictor of longer-term and sustained treatment response to continued oral iron supplementation. Day-14 Hb may be a useful tool for clinicians in determining whether and when to transition patients from oral to IV iron. While our findings provide a practical approach to the monitoring of oral iron treatment response in iron-deficiency anemia, we acknowledge that our findings have potential biases inherent in posthoc analyses. Also, multiple comparisons that were performed in our analyses create the chance of a Type 1 error in our conclusions. Nonetheless, our findings are consistent with the results of a pivotal RCT that included a 14-day oral iron run-in phase prior to randomization of IDA subjects with various etiologies to additional oral iron vs. IV ferric carboxymaltose. 9 In this study, 143 of 374 subjects (38.4%) who completed the prospective oral iron run-in study phase achieved Hb >1g/dL. Future clinical trials that examine the utility of day-14 Hb in this regard are needed to confirm these findings. Given that iron deficiency and iron-deficiency anemia are recognized common medical conditions, further efforts to characterize medication adherence and treatment effectiveness will optimize and promote global health. between the end of the first cycle and week 9 of the study. (those with a ≥ 1 g/dL rise in hemoglobin by day 14) were more likely to manifest durable and more robust increments than non-responders (those with <1 g/dL rise in hemoglobin by day 14).
